In addition, the expression levels of the anti-inflammatory IL-10 and IL-22 in the DSS + GMEVs group were considerably greater than in the DSS group, with this difference perhaps underlying the beneficial effect of GMEV pre-treatment for relieving colitis (Figure 5C,F). This evidence concerns the gene IL22 and colitis.